State

• Many people are now using AI tools like ChatGPT, Claude or Gemini to get advice, find information or summarise longer passages of text.
• But our recent research demonstrates how generative AI can be used for much more than this, returning results in different formats.
• On the one hand, AI tools are neutral – they can be used for good or ill depending on one’s intent.

1. Imagining what lies beyond the frame

• Adobe’s recently developed “generative expand” tool allows users to expand the canvas of their photos and have Photoshop “imagine” what is happening beyond the frame.
• You might do this when trying to edit a square Instagram photo to fit a 4x6 inch photo frame.

2. Visualising the past or the future

• Photography was only invented within the past 200 years, and camera-equipped smartphones within the last 25.
• That leaves us with plenty of things that existed before cameras were common, yet we might want to visualise them.
• NASA currently works with artists to illustrate concepts we can’t see, but artists could also draw on AI to help create these renderings.

3. Brainstorming how to visualise difficult concepts

• As one of the deepest places on Earth, few people have ever seen it firsthand.
• Or creating a layered illustration that shows the flora and fauna that live at each of the ocean’s five zones above the trench.

4. Visualising data

• For example, you might upload a spreadsheet to ChatGPT 4 and ask it to visualise the results.
• Or, if the data is already publicly available (such as Earth’s population over time), you might ask a chatbot to visualise it without even having to supply a spreadsheet.

5. Creating simple moving images

You can create a simple yet effective animation by uploading a photo to an AI tool like Runway and giving it an animation command, such as zooming in, zooming out or tracking from left to right. That’s what I’ve done with this historical photo preserved by the State Library of Western Australia.

• I used this description to create the following video:
  Tracking shot from left to right of the snowy mountains of Nagano, Japan.
• Tracking shot from left to right of the snowy mountains of Nagano, Japan.

6. Generating a colour palette or simple graphics

• In these cases, having a consistent colour palette can help unify your design.
• You can ask generative AI services like Midjourney or Gemini to create a colour palette for you based on the event or its vibe.
• This is true for both browser-based generators like Adobe Firefly, as well as desktop apps with built-in AI, like Adobe Illustrator.

T.J. Thomson receives funding from the Australian Research Council. He is an affiliate with the ARC Centre of Excellence for Automated Decision Making & Society.

• The completed comments form should be sent to
  [email protected]
  10
  11
  Keywords

  Committee on Herbal Medicinal Products; HMPC; European Union herbal
  monographs; European Union list of herbal substances, preparations and
  combinations thereof for use in traditional herbal medicinal products; herbal
  medicinal products; traditional herbal medicinal products; traditional use;
  well-established medicinal use; benefit-risk assessment; assessment report

  12

  1
  2

  Changes introduced in section 6 Overall conclusions.

• Peer-reviewer

  If not the same peer-reviewer
  since last version, all peerreviewers should be listed, and
  the version specified in
  brackets.

• 22

  23

  
  on
  .

• It is a working

  24

  document, not yet edited, and shall be further developed after the release for consultation of the

  25

  
  .

• The principle of the template is to make clear
  distinctions between presentation of data (methodology and results)
  and the assessment of the data (?assessor?s comment?).
• likely from an article but it seems it is concluded by
  the rapporteur; ?According to the author? to be added.
• Chapters with
  a heading including the word ?conclusion? should include a summary
  of all critical assessment of the assessor for that particular
  chapter.
• If an assessor?s comment is not needed, the Rapporteur
  should delete the box inserted in the template.
• ?
  The report should be sufficiently detailed to allow for secondary
  assessment of the available data by other HMPC experts.
• Overview of available pharmacokinetic data regarding the herbal substance(s), herbal
  preparation(s) and relevant constituents thereof ........................................................... 16

  97
  98

  3.3.

• Overall conclusions on clinical pharmacology and efficacy ........................................ 27

  Assessment report on
  EMA/HMPC/418902/2005

  Page 4/41

  119

  5.

• This sections is related to
  available quality standards and there is no need to repeat information
  on all preparations included in the monograph.
• Search and assessment methodology

  161

  The Rapporteur shall undertake a comprehensive search of relevant
  scientific literature and articles, Acts of law and regulations and
  other relevant sources.

• Cross-reference to the list of
  references in Annex, which should list separately the references
  supporting the assessment report.
• 143
  144
  145

  150
  151
  152
  153
  154

  162
  163
  164
  165
  166
  167
  168
  169
  170
  171
  172
  173
  174
  175

  Herbal substance(s)

  Herbal preparation(s)

  Relevant constituents for this assessment report

  Examples of scientific databases to be searched are Medline, PubMed,
  Cochrane Database of Systematic Reviews, EMBASE etc.

• Assessment report on
  EMA/HMPC/418902/2005

  Page 6/41

  176
  177
  178
  179
  180
  181
  182
  183
  184
  185
  186
  187
  188
  189
  190
  191
  192

  Additional relevant references could also be retrieved from the checked
  references.

• Examples of books are Hagers Handbuch, The Complete German
  Commission E Monographs, PDR for herbal medicines etc.
• In addition, information from non-EU regulatory
  authorities for examples Health Canada monographs or WHO monographs
  could be searched, if relevant to herbal substances and preparations in
  EU.
• 221

  225
  226
  227

  232

  When the assessment report is revised, the rapporteur should briefly
  summarise the main changes under this section.

• Data are collected using the template entitled ?Document
  for information exchange for the preparation of the assessment report
  for the development of European Union monographs and for inclusion of
  herbal substance(s), preparation(s) or combinations thereof in the
  list? (EMEA/HMPC/137093/2006).
• Assessment report on
  EMA/HMPC/418902/2005

  Page 8/41

  Herbal substance/

  Indication

  Posology and
  method of

  preparation

  administration

  Posology, age
  groups,
  pharmaceutical
  form, method of
  administration,
  duration of use
  As reported in
  the market
  overview

  As reported in
  the market
  overview

  As reported in
  the market
  overview.

• Assessment report on
  EMA/HMPC/418902/2005

  Page 10/41

  Herbal substance/

  Indication/Medicinal

  Posology and

  preparation

  use

  method of
  administration

  Posology, age
  groups,
  pharmaceutical
  form, method of
  administration,
  duration of use

  Regulatory Status

  Type of
  regulatory
  status where
  possible, date,
  Country

  287

  This overview is not exhaustive.

• Clinical Safety/Pharmacovigilance

  836
  837
  838
  839
  840
  841

  See ?Assessment of clinical safety and efficacy in the preparation of
  EU herbal monographs for well-established and traditional herbal
  medicinal products?(EMA/HMPC/104613/2005) for further details.

• Overall conclusions on clinical safety

  1067

  1068

  In terms of structure, the conclusion should follow the presentation of
  the results above.

• Overall conclusions

  1092

  1093

  1101

  Describe key aspects only briefly, these will already have been
  described in detail in the respective sections.

• This section should
  cover all recommended ?well-established use? and ?traditional use?
  indications and conclusions shall be provided for each therapeutic
  indication and each herbal preparation.
• 1102

  Well established use monograph

  1103
  1104

  The clinical studies supporting well-established use should be
  specified for each therapeutic indication and each herbal preparation.

• The choice for the wording of traditional use indications vis-?vis existing wordings in monographs in the same therapeutic area should
  be briefly discussed/justified.
• 1153

  List entry

  1154

  The conclusions should include a statement pointing to the
  possibility/non-possibility to support a European Union list entry.

• The Federal Trade Commission today issued a report to Congress detailing the FTC’s law enforcement cooperation with state attorneys general (AGs) nationwide and presenting best practices to ensure continued effective collaboration.
• The report, directed by the FTC Collaboration Act of 2021, “Working Together to Protect Consumers: A Study and Recommendations on FTC Collaboration with the State Attorneys General” makes legislative recommendations that would enhance these efforts, including reinstating the Commission’s authority to seek money for defrauded consumers and providing it with the independent authority to seek civil penalties.
• The report is divided into three sections: 1) The FTC’s Existing Collaborative Efforts with State Attorneys General to Prevent, Publicize, and Penalize Frauds and Scams; 2) Recommended Best Practices to Enhance Collaboration; and 3) Legislative Recommendations to Enhance Collaboration Efforts.
• Follow the FTC on social media, read consumer alerts and the business blog, and sign up to get the latest FTC news and alerts.

• Synnovis, the South East London hospital outsourcing contract grew 12.2% in 2023 and contributed 0.6pts to the overall 2023 underlying organic growth.
• FY 2023 adjusted EBITDA (AEBITDA) was €438 million (FY 2022: €753 million) while adjusted operating profit (AOP) was €194 million (FY 2022: €508 million) with margins of 16.6% (FY 2022: 23.2%) and 7.4% (FY 2022: 15.6%), respectively.
• In FY 2023, adjusted net profit (Group share) was €44 million (FY 2022: €342 million), mainly due to lower COVID-19 testing volumes and higher net finance costs.
• FY 2023 unlevered free cash flow (uFCF) was €74 million (FY 2022: €312 million).